NEW YORK (GenomeWeb News) – Fluidigm today announced its collaboration with Novartis to develop a non-invasive fetal diagnostic test has ended.

The collaboration ended on May 1, when Novartis chose not to exercise an option to exclusively license Fluidigm's digital PCR technology. Fluidgm added that it successfully achieved all of its technical feasibility milestones in the first phase of the collaboration and received all milestone payments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.